Drug executives say only their GLP-1 drugs are safe for treating obesity and diabetes as they wage a yearlong campaign to stop independent labs from producing cheaper versions. Former Novo Nordisk CEO ...

Patients without diabetes treated with GLP-1s for weight loss are remaining on the drugs without gaps, and switching drugs when needed may help sustain persistence.

A sweeping review of dozens of clinical trials suggests that today’s most widely used GLP-1 receptor agonist drugs produce broadly consistent weight-loss results across age, race, ethnicity, and ...

Medicare had banned coverage of weight-loss drugs for 23 years, and what happens next isn't as simple as the headlines suggest.

A new study finds that GLP-1 drugs may help to stabilize chronic migraines, with patients seeing fewer ER visits and less ...

MASLD, affecting 30% of adults, is driven by obesity and insulin resistance, leading to severe liver conditions if untreated. GLP-1 RAs, such as liraglutide and semaglutide, show strong evidence for ...

Taking popular GLP-1 class weight loss drugs like Ozempic and Wegovy could be linked to a higher risk of developing osteoporosis, gout and a condition that causes severe bone softening compared to ...

Ozempic started the weight-loss drug frenzy, and it continues to be a famous name in the fight against obesity, even though it's not approved for that purpose. The blockbuster medication is meant to ...